HOME   |    PDF   |   


Title

Risk assessment for arrhythmia among Indians after CoViD-19 vaccination

 

Authors

S. Sunita1, Madhu Bala Negi2, Moti Lal3, Chandan Kumar*, 1 & Manish Kumar1

 

Affiliation

1Department of Physiology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India; 2Department of Medicine, ABVIMS, New Delhi, India; 3Lady Hardinge Medical College, New Delhi, India; *Corresponding author

 

Email

S Sunita - E-mail: dr.sunitaigims@gmail.com

Madhu Bala Negi - E-mail: madhu.negi2007@gmail.com

Moti Lal - E-mail: motilalnegi@gmail.com

Chandan Kumar - E-mail: dr.chandankumar2010@gmail.com

Manish Kumar - E-mail: krmanish77@gmail.com

 

Article Type

Research Article

 

Date

Received May 1, 2024; Revised May 31, 2024; Accepted May 31, 2024, Published May 31, 2024

 

Abstract

The Oxford/AstraZeneca CoViD-19 vaccine delivers viral proteins directly to the host body. This triggers an adaptive immune response, giving the body viral immunity. Post-vaccination myocarditis is usually moderate and transient, recovering quickly with conservative treatment. Occasionally, myocardial fibrosis or scarring might disrupt the conduction route, causing irregular cardiac rhythms and ECGs. We looked for ECG abnormalities in a small cohort of participants after 52 weeks after receiving the Oxford/AstraZeneca CoViD-19 vaccination.

 

Keywords

ECG, Covieshield vaccine, myocarditis, arrhythmia.

 

Citation

Sunita et al. Bioinformation 20(5): 430-433 (2024)

 

Edited by

Vini Mehta

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.